Perspective Therapeutics secures EU orphan drug designation for its lead‑212 radiopharmaceutical targeting GEP‑NETs
Executive summary: Perspective Therapeutics received European Orphan Medicinal Product Designation for its lead‑212 VMT‑α‑NET therapy aimed at gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). Orphan status confers regulatory benefits, including possible 10‑year market exclusivity in the EU, reduced fees and eligibility for grant support, which can accelerate development and commercialization of a niche radiopharmaceutical.
Who is involved: Perspective Therapeutics (NYSE American: CATX), the European Medicines Agency, and patients with GEP‑NETs.
Likely next: The company will advance clinical development of the therapy, seek additional regulatory interactions, and explore partnership or funding opportunities to move the program toward market.
Perspective Therapeutics announced that the European Medicines Agency has granted orphan medicinal product designation to its investigational therapy [212Pb]VMT‑α‑NET for gastroenteropancreatic neuroendocrine tumors. The designation provides regulatory incentives such as protocol assistance, fee reductions and potential market exclusivity upon approval. It underscores progress in the company’s radiopharmaceutical pipeline and may facilitate future partnership or financing discussions.
Timeline
- — Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs (GlobeNewswire)
- — Denison Announces Completion of Site Preparation Activities and Commencement of Full-Scale Construction at Phoenix ISR Uranium Mine (PR Newswire)
Analysis — what this means
Sectors affected
- Radiopharmaceuticals